J. Jacobson

发表

Advances in Biology and Therapy of Multiple Myeloma

Bart Barlogie, Joth Jacobson, R. Bataille, 2013, Springer New York.

Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009

R. Holcombe, S. Dakhil, J. Jacobson, 1999, Cancer Immunology, Immunotherapy.

Partitioning and peeling for constructing prognostic groups

Michael LeBlanc, Joth Jacobson, M. LeBlanc, 2002, Statistical methods in medical research.

Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study

S. Kasner, J. Jacobson, L. Thomassen, 2017, International journal of stroke : official journal of the International Stroke Society.

Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060

L. Hutchins, J. Jacobson, M. Valdivieso, 1996, Cancer.

Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157)

G. Weiss, D. Gandara, J. Jacobson, 2004, Investigational New Drugs.

Results of the U.S. multicenter pivotal study of the HELEX septal occluder for percutaneous closure of secundum atrial septal defects.

J. Jacobson, K. Kanter, L. Latson, 2007, Journal of the American College of Cardiology.

Does Leucovorin Alter the Intratumoral Pharmacokinetics of 5-Fluorouracil (5-FU)? A Southwest Oncology Group Study

C. Presant, J. Jacobson, W. Wolf, 2002, Investigational New Drugs.

DTPACE: A n E ffective, N ovel C ombination C hemotherapy W ith Thalidomide f or P reviously T reated P atients W ith M yeloma

B. Barlogie, N. Munshi, G. Tricot, 2003 .

Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).

J. Crowley, B. Barlogie, M. Dhodapkar, 2003, Seminars in oncology.

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

B. Barlogie, E. Anaissie, G. Tricot, 2003, Experimental hematology.

Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.

J. Crowley, J. Jacobson, R. Alexanian, 2001, Seminars in hematology.

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

Bart Barlogie, Louis Fink, Joth Jacobson, 2004, British journal of haematology.

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.

Bart Barlogie, Joth Jacobson, B. Barlogie, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1997, Blood.

MDS‐type abnormalities within myeloma signature karyotype (MM‐MDS): only 13% 1‐year survival despite tandem transplants

B. Barlogie, J. Shaughnessy, G. Tricot, 2003, British journal of haematology.

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.

B. Barlogie, J. Shaughnessy, J. Jacobson, 2003, Blood.

Disease Heterogeneity, Cytogenetic Status, and Overall Survival Telomerase and Telomere Length in Multiple Myeloma: Correlations With

B. Barlogie, J. Shaughnessy, J. Jacobson, 2022 .

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.

Bart Barlogie, Louis Fink, Joth Jacobson, 2003, Clinical lymphoma.

in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities,

B. Barlogie, J. Shaughnessy, S. Jagannath, 2013 .

(Southwest Oncology Group S9003) Waldenström macroglobulinemia: results of United States intergroup trial Prognostic factors and response to fludarabine therapy in patients with

J. Crowley, B. Barlogie, M. Dhodapkar, 2013 .

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.

J. Crowley, B. Barlogie, J. Jacobson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

J. Crowley, B. Barlogie, J. Jacobson, 2003, British journal of haematology.

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.

F. Zhan, B. Barlogie, J. Shaughnessy, 2003, Blood.

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II

B. Barlogie, J. Shaughnessy, E. Anaissie, 2003, British journal of haematology.

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia : results of United States intergroup trial ( Southwest Oncology Group S 9003 )

J. Crowley, B. Barlogie, M. Dhodapkar, 2001 .

Some Exploratory Tools for Survival Analysis

John Crowley, Michael LeBlanc, Joth Jacobson, 1997 .

Treatment of multiple myeloma.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004, Blood.

A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339)

G. Weiss, J. Jacobson, J. Kuebler, 2000, Investigational New Drugs.

for Previously Untreated Multiple Myeloma Superiority of Tandem Autologous Transplantation Over Standard Therapy

B. Barlogie, B. Cheson, S. Jagannath, 2013 .

Fracture of the GORE HELEX septal occluder: Associated factors and clinical outcomes

J. Jacobson, L. Latson, T. Fagan, 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Analysis of factors related to successful transcatheter closure of secundum atrial septal defects using the HELEX septal occluder.

J. Jacobson, L. Latson, J. Rhodes, 2006, American heart journal.

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

J. Crowley, B. Barlogie, M. Dhodapkar, 2001, Blood.

Treatment of Multiple Myeloma

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

Inclusion of black Americans in oncology clinical trials: the Louisiana State University Medical Center experience.

R. Holcombe, C. Moinpour, J. Jacobson, 1999, American journal of clinical oncology.

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study.

G. Weiss, J. Jacobson, J. Macdonald, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

J. Crowley, B. Barlogie, M. Dhodapkar, 2001, Blood.